NCT07301268 2026-04-08
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Mayo Clinic
Phase 2 Recruiting
Clinical Trials
35 trialsNCT07283731 2026-04-06
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT03197506 2026-03-25
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
Mayo Clinic
Phase 2 Active not recruiting
NCT06898970 2026-03-17
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
University of California, San Francisco
Phase 2 Recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT03316573 2026-02-10
Pembrolizumab in Neoplasms or Lymphomas
Dana-Farber Cancer Institute
Phase 2 Suspended
NCT04332874 2026-01-30
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05846724 2026-01-22
PULSAR
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Phase 2 Withdrawn
NCT05465954 2026-01-12
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Mayo Clinic
Phase 2 Recruiting
NCT07089992 2025-12-16
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT02406781 2025-12-10
PEMBROSARC
Institut Bergonié
Phase 2 Completed
NCT06128863 2025-12-08
EFTISARC-NEO
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Active not recruiting
NCT06116578 2025-12-01
NeoSarc
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT03069378 2025-10-29
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03899805 2025-08-28
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05156268 2025-08-17
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02337686 2025-08-15
Pembrolizumab in Treating Patients With Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05679921 2025-07-16
Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma
Yonsei University
Phase 2 Recruiting
NCT03414229 2025-05-02
A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06494787 2025-02-24
SOC-2320
Sarcoma Oncology Research Center, LLC
Phase 2 Withdrawn
NCT06794645 2025-01-27
Pembrolizumab and Pemetrexed for Progressive Chordoma
Saint John's Cancer Institute
Phase 2 Recruiting
NCT02636725 2024-07-12
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
University of Miami
Phase 2 Completed
NCT03291054 2024-06-11
Epacadostat and Pembrolizumab in Patients With GIST
Columbia University
Phase 2 Terminated
NCT03012620 2024-02-28
AcSé
UNICANCER
Phase 2 Completed
NCT03056001 2023-11-18
Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma
Wake Forest University Health Sciences
Phase 2 Completed
NCT03349450 2023-11-02
SPiReL
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT03063632 2023-10-25
Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT05961761 2023-07-27
PROPANE
Herlev and Gentofte Hospital
Phase 2 Recruiting
NCT02798406 2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2 Completed
NCT02691026 2021-06-23
A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery
Oslo University Hospital
Phase 2 Terminated
NCT02423863 2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2 Completed
NCT03013127 2020-10-14
PROMO
Oslo University Hospital
Phase 2 Terminated
NCT02301039 2020-09-29
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT03697824 2019-10-29
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
GlaxoSmithKline
Phase 2 Withdrawn
NCT03469804 2019-10-21
KAPKEY
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown